证券研究报告·北交所公司点评报告·专用设备 广厦环能（873703） 2025 中报点评：短期行业需求承压，公司积 极开拓新领域及新市场需求 增持（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 524.38 | 540.98 | 426.50 | 480.21 | 540.97 | | 同比 | 10.14 | 3.17 | (21.16) | 12.59 | 12.65 | | 归母净利润（百万元） | 125.64 | 154.17 | 113.35 | 127.61 | 140.67 | | 同比 | (4.28) | 22.71 | (26.48) | 12.58 | 10.23 | | EPS-最新摊薄（元/股） | 0.83 | 1.02 | 0.75 | 0.85 | 0.93 | | P/E（现价&最新摊薄） | 19.47 | 15.87 | 21.58 | 19.17 | 17.39 | [Tab ...

Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - The company's performance has declined due to a drop in demand, particularly in the photovoltaic sector, leading to a significant decrease in revenue and profit margins [7] - The demand for silicon-carbon anodes is gradually increasing, and the company is actively expanding its production of zone-refined polysilicon, which is expected to become a new growth driver [7] - The forecast for the company's net profit has been adjusted downwards for 2025-2027, with expected figures of -48 million, 8 million, and 46 million respectively, reflecting a significant decline in profitability [7] Financial Summary - Total revenue for 2023 is projected at 1,120.69 million, with a year-on-year growth of 17.55%, but is expected to decline to 510.59 million in 2025, a decrease of 27.62% [1] - The net profit attributable to shareholders is forecasted to be 308.23 million in 2023, dropping to -47.77 million in 2025, indicating a year-on-year decline of 161.50% [1] - The latest diluted EPS is expected to be -0.11 in 2025, compared to 0.73 in 2023 [1] - The company's P/E ratio is projected to be -107.27 in 2025, reflecting the anticipated losses [1] - The company's total assets are estimated to be 2,147 million in 2024, with a slight increase to 2,385 million by 2027 [8]

证券研究报告·公司点评报告·医疗器械 新产业（300832） 2025 年中报点评：海外推进顺利，期待逐季 改善 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 3,930 | 4,535 | 4,897 | 5,707 | 6,619 | | 同比（%） | 28.97 | 15.41 | 7.98 | 16.53 | 15.98 | | 归母净利润（百万元） | 1,654 | 1,828 | 1,849 | 2,252 | 2,757 | | 同比（%） | 24.53 | 10.57 | 1.13 | 21.78 | 22.46 | | EPS-最新摊薄（元/股） | 2.10 | 2.33 | 2.35 | 2.87 | 3.51 | | P/E（现价&最新摊薄） | 24.90 | 22.52 | 22.27 | 18.29 | 14.93 | [Table_Tag] [Table_Summary] ...

Investment Rating - The report maintains a "Buy" rating for Pinduoduo (PDD) [1] Core Insights - Pinduoduo achieved revenue of RMB 103.99 billion in Q2 2025, a year-on-year increase of 7.1%, aligning with Bloomberg's consensus estimate of RMB 103.98 billion. The Non-GAAP net profit was RMB 32.71 billion, a decrease of 5.0% year-on-year, but significantly above the market expectation of RMB 22.39 billion. The net profit margin stood at 31.5%, down 4.0 percentage points year-on-year [7][12] - Advertising revenue grew significantly by 13.4% year-on-year to RMB 55.7 billion, exceeding market expectations, while commission revenue increased by only 0.7% year-on-year to RMB 48.28 billion, falling short of expectations [14] - The company continues to focus on high-quality development and platform ecosystem construction, implementing measures such as "reduction, support, and governance" across various operational aspects [7][12] Revenue and Profitability - The overall gross margin for Q2 2025 was 55.9%, reflecting a decline of 9.4 percentage points year-on-year and 1.3 percentage points quarter-on-quarter [19] - The report indicates a decrease in sales and management expense ratios, with sales expense ratio at 26.2% (down 0.7 percentage points year-on-year) and management expense ratio at 1.5% (down 0.4 percentage points year-on-year). R&D expense ratio increased to 3.5%, up 0.5 percentage points year-on-year [22] Earnings Forecast and Valuation - The report adjusts the Non-GAAP net profit forecasts for 2025-2027 to RMB 100.40 billion, RMB 126.46 billion, and RMB 152.41 billion, respectively. The corresponding PE ratios for these years are projected to be 12.1, 9.6, and 7.9 times [23] - The report emphasizes the need for continued investment in ecosystem development due to intensified competition in the e-commerce sector [23]

Investment Rating - The report maintains a "Buy" rating for BYD Electronics (00285.HK) [1] Core Views - The company has shown stable growth, with new momentum from automotive and new intelligent products [1] - Revenue for the first half of 2025 reached 80.61 billion RMB, a year-on-year increase of 2.6%, while net profit attributable to shareholders was 1.73 billion RMB, up 14.0% year-on-year [7] - The report highlights the company's strong performance in consumer electronics, AI data center products, and the electric vehicle sector, indicating robust growth potential across various business lines [7] Summary by Sections Financial Performance - Total revenue for 2023 is projected at 130.404 billion RMB, with a year-on-year growth of 20.83% [1] - Net profit attributable to shareholders is expected to reach 4.041 billion RMB in 2023, reflecting a significant year-on-year increase of 117.56% [1] - The earnings per share (EPS) for 2025 is estimated at 2.35 RMB, with a price-to-earnings (P/E) ratio of 17.59 based on the latest diluted EPS [1] Business Segments - Consumer electronics revenue for the first half of 2025 was 60.947 billion RMB, a decrease of 3.7% year-on-year, but the company is focusing on high-value products to enhance profitability [7] - New intelligent product revenue reached 7.209 billion RMB, with significant growth in AI data center products and internal applications of robotics [7] - The electric vehicle business generated 12.450 billion RMB in revenue, a year-on-year increase of 60.50%, driven by the demand for smart cockpit and driving products [7] Future Projections - The report adjusts the expected net profit for 2025 to 5.300 billion RMB, with further increases projected for 2026 and 2027 [7] - The anticipated P/E ratios for 2025, 2026, and 2027 are 17.6, 14.7, and 12.6 respectively, indicating a favorable valuation outlook [7]

Investment Rating - The report maintains an "Accumulate" rating for the company [7] Core Views - The company turned profitable in H1 2025, with significant growth in bismuth materials and semiconductor equipment businesses [7] - H1 2025 revenue reached 699 million yuan, a substantial increase of 247.8% year-on-year, driven primarily by bismuth materials and deep processing business [7] - The company is expanding its semiconductor equipment segment, particularly in ion implantation machines, while also enhancing its bismuth materials business [7] Financial Summary - Total revenue forecast for 2023A is 964.61 million yuan, with a projected increase to 1,982.74 million yuan by 2027E, reflecting a growth rate of 40.18% [7] - The net profit attributable to the parent company is expected to rise from 151.15 million yuan in 2023A to 514.54 million yuan in 2027E, indicating an 81.80% growth in 2025E [7] - The latest diluted EPS is projected to increase from 0.16 yuan in 2023A to 0.55 yuan in 2027E [7] - The current market capitalization corresponds to dynamic P/E ratios of 74, 45, and 28 for 2025E, 2026E, and 2027E respectively [7] Business Performance - The company achieved a gross margin of 27.5% in H1 2025, although it faced pressure due to lower margins in new bismuth materials [7] - The net profit margin improved significantly to -2.6% in H1 2025, a year-on-year increase of 57.1 percentage points [7] - The company’s cash flow from operating activities was -3.294 billion yuan in H1 2025, indicating short-term cash flow pressure [7] Strategic Developments - The company is solidifying its position as a domestic leader in ion implantation equipment while expanding into larger market segments such as etching and thin film deposition [7] - The bismuth materials business is rapidly growing, benefiting from rising domestic prices and increased demand from downstream sectors [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has achieved steady growth in performance, with a focus on accelerating platform-based layout in the semiconductor sector [1] - The semiconductor equipment business is experiencing rapid growth, with a revenue increase of 29.51% year-on-year in the first half of 2025 [7] - The company is expected to benefit from the domestic substitution trend in the semiconductor equipment industry [7] Financial Performance Summary - Total revenue for 2023 is projected at 22,079 million RMB, with a year-on-year growth of 50.32% [1] - Net profit attributable to the parent company for 2023 is estimated at 3,899 million RMB, reflecting a year-on-year increase of 65.73% [1] - The company’s earnings per share (EPS) for 2023 is forecasted to be 5.40 RMB [1] Revenue and Profit Forecast - Revenue is expected to grow to 29,838 million RMB in 2024, 38,564 million RMB in 2025, and reach 57,163 million RMB by 2027 [1] - Net profit attributable to the parent company is projected to be 5,621 million RMB in 2024, 7,344 million RMB in 2025, and 11,265 million RMB in 2027 [1] - The company’s dynamic P/E ratios are forecasted to be 47.82 for 2024, 36.60 for 2025, and 23.86 for 2027 [1] Product Performance - The electronic process equipment segment generated revenue of 152.58 billion RMB in the first half of 2025, up 33.89% year-on-year, contributing over 85% to total revenue [7] - The company launched its first ion implantation machine and electroplating equipment at the 2025 SEMICON exhibition, expanding its product line [7] Inventory and Cash Flow - As of the end of Q2 2025, the company’s inventory reached 311 billion RMB, a 47% increase year-on-year, indicating a strong order backlog [7] - The net cash flow from operating activities for the first half of 2025 was -31.91 billion RMB, primarily due to increased cash payments for goods and services [7]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company achieved a revenue of 1.57 billion in the first half of 2025, representing a year-on-year growth of 68%, significantly exceeding market expectations [7] - The overall chip shipment reached 1.98 million units in the first half of 2025, doubling year-on-year, with mid-to-high-end chip shipments increasing sixfold [7] - The average price per chip in the first half of 2025 was 393 yuan, up 106% year-on-year, driven by an improved product mix [7] - The company has established partnerships with 27 OEMs (42 brands), with over 310 models confirmed, maintaining a leading market share in China [7] - R&D expenses reached 2.3 billion in the first half of 2025, a 62% increase year-on-year, aimed at enhancing core competitiveness [7] - The report forecasts revenues of 3.66 billion, 5.36 billion, and 8.05 billion for 2025, 2026, and 2027 respectively, with corresponding P/S ratios of 36.4, 24.8, and 16.6 [7] Financial Summary - The company reported a net profit of -13.3 billion in the first half of 2025, with an adjusted net profit of -13 billion [7] - The projected total revenue for 2023, 2024, 2025, 2026, and 2027 is 1.55 billion, 2.38 billion, 3.66 billion, 5.36 billion, and 8.05 billion respectively, with year-on-year growth rates of 71.32%, 53.62%, 53.52%, 46.60%, and 50.00% [1][8] - The projected net profit for the same years is -6.74 billion, 2.35 billion, -2.45 billion, -1.41 billion, and 0.40 billion, with corresponding year-on-year growth rates of 22.71%, 134.82%, -204.40%, 42.57%, and 128.68% [1][8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has exceeded performance expectations in the first half of 2025, leading to an upward revision of the full-year performance guidance [8] - The revenue for the first half of 2025 reached USD 2.43 billion, a year-on-year increase of 42%, driven by the strong sales of core product Zebutini in the US and continued growth in Europe [8] - The company is expected to maintain steady revenue growth over the next three years, with significant profit release anticipated in the coming years [8] Financial Forecasts - Total revenue projections are as follows: - 2023: CNY 17,423 million - 2024: CNY 27,214 million (YoY +56.19%) - 2025: CNY 36,720 million (YoY +34.93%) - 2026: CNY 44,798 million (YoY +22.00%) - 2027: CNY 55,998 million (YoY +25.00%) [1][9] - The net profit attributable to the parent company is forecasted to improve significantly: - 2023: CNY -6,715.86 million - 2024: CNY -4,978.29 million - 2025: CNY 812.75 million (YoY +116.33%) - 2026: CNY 4,168.46 million (YoY +412.88%) - 2027: CNY 9,542.78 million (YoY +128.93%) [1][9] - The latest diluted EPS projections are: - 2023: CNY -4.70 - 2024: CNY -3.48 - 2025: CNY 0.57 - 2026: CNY 2.91 - 2027: CNY 6.67 [1][9] Key Catalysts - Important catalysts include the upcoming data readout for Sonrotoclax (BCL2 inhibitor) in late 2025 and the initiation of head-to-head trials against rival therapies [8] - The company is also advancing its pipeline in solid tumors and inflammation/immunology, with several clinical trials expected to start in 2026 [8]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company has shown improvement in cash flow and continues to advance its "Three New and Two Transformations" strategy [8] - In the first half of 2025, the company achieved a revenue of 81.106 billion yuan, representing a year-on-year increase of 5.10%, and a net profit attributable to shareholders of 1.446 billion yuan, up 19.70% year-on-year [8] - The company successfully issued public REITs for pharmaceutical warehousing and logistics, contributing a net profit of 438 million yuan [8] - The report adjusts the net profit forecasts for 2025-2027 to 2.694 billion yuan, 2.818 billion yuan, and 3.108 billion yuan respectively, corresponding to a PE ratio of 10, 9, and 8 times [8] Financial Performance Summary - Total revenue forecast for 2023A is 150.14 billion yuan, with a projected growth of 6.92% [1] - The net profit attributable to shareholders for 2023A is forecasted at 2.174 billion yuan, with a year-on-year growth of 4.27% [1] - The latest diluted EPS for 2023A is estimated at 0.43 yuan per share [1] - The company’s operating cash flow is expected to increase significantly, with a net cash flow from operating activities of 6.75 billion yuan in 2025E [9]